

SHITARA, K. et al.

Appl. No. 10/009,723

October 14, 2005

AMENDMENT AFTER FINAL REJECTION

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-10. (Canceled)

11. (Currently Amended) A method for detecting differentiation from a hematopoietic stem cell into a monocyte and/or a macrophage, which comprises:

differentiating a hematopoietic stem cell into a monocyte and/or a macrophage in contacting a specimen derived from cells or tissues of a person to be tested,

contacting the specimen with an antibody against a human VEGF receptor Flt-1, to thereby detect a monocyte and/or a macrophage in

detecting whether or not the antibody against a human VEGF receptor Flt-1 reacts with the specimen, and

determining the specimen with which the antibody against a human VEGF receptor Flt-1 reacts as a specimen in which a hematopoietic stem cell differentiates into a monocyte and/or macrophage.

Claim 12. (Canceled)

13. (Previously Presented) The method according to claim 11, wherein the antibody against a human VEGF receptor Flt-1 is a polyclonal antibody or a monoclonal antibody.

SHITARA, K. et al.

Appl. No. 10/009,723

October 14, 2005

AMENDMENT AFTER FINAL REJECTION

14. (Previously Presented) The method according to claim 13, wherein the monoclonal antibody is an antibody selected from the group consisting of an antibody produced by a hybridoma, a humanized antibody and antibody fragments thereof.

15. (Previously Presented) The method according to claim 14, wherein the antibody produced by a hybridoma is an antibody selected from the group consisting of an antibody produced by hybridoma KM1730 (FERM BP-5697), an antibody produced by hybridoma KM1731 (FERM BP-5718), an antibody produced by hybridoma KM1732 (FERM BP-5698), an antibody produced by hybridoma KM1748 (FERM BP-5699) and an antibody produced by hybridoma KM1750 (FERM BP-5700).

16. (Previously Presented) The method according to claim 14, wherein the humanized antibody is an antibody selected from the group consisting of a human chimeric antibody and a human complementarity determining region-grafted antibody.

17. (Currently Amended) The method according to claim 16, wherein the human chimeric antibody is an antibody selected from the group consisting of:

an antibody comprising the H chain variable region encoded by DNA contained in *Escherichia coli* XL-1 Blue MRF'/KM1732HA2 (FERM BP-6354) and the L chain variable region encoded by DNA contained in *Escherichia coli* XL-1 Blue MRF'/KM1732L2-1 (FERM BP-6352), and

an antibody comprising the H chain variable region encoded by DNA contained in *Escherichia coli* XL-1 Blue MRF'/KM1750H2-1 (FERM BP-6353) and the L chain

SHITARA, K. et al.

Appl. No. 10/009,723

October 14, 2005

AMENDMENT AFTER FINAL REJECTION

variable region encoded by DNA contained in *Escherichia coli* XL-1 Blue

MRF'/KM1750L3-1 (FERM BP-6355).

18. (Currently Amended) The method according to claim 16, wherein the human complementarity determining region-grafted antibody is an antibody selected from the group consisting of:

an antibody comprising the H chain variable region DNA contained in *Escherichia coli* DH5 α /pHKM1750HV0 DH5 α /phKM1750HV0 (FERM BP-6719) and the L chain variable region DNA contained in *Escherichia coli* XL1-Blue/phKM1750LV0(I) (FERM BP-6716),

an antibody comprising the H chain variable region DNA contained in *Escherichia coli* DH5 α /pHKM1750HV0 DH5 α /phKM1750HV0 (FERM BP-6719) and the L chain variable region DNA contained in *Escherichia coli* XL1-Blue/phKM1750LV0(IV) (FERM BP-6717),

an antibody comprising the H chain variable region DNA contained in *Escherichia coli* DH5 α /pHKM1750HV3 DH5 α /phKM1750HV3 (FERM BP-6720) and the L chain variable region DNA contained in *Escherichia coli* XL1-Blue/phKM1750LV0(I) (FERM BP-6716),

an antibody comprising the H chain variable region DNA contained in *Escherichia coli* DH5 α /pHKM1750HV3 DH5 α /phKM1750HV3 (FERM BP-6720) and the L chain variable region DNA contained in *Escherichia coli* XL1-Blue/phKM1750LV0(IV) (FERM BP-6717),

SHITARA, K. et al.

Appl. No. 10/009,723

October 14, 2005

AMENDMENT AFTER FINAL REJECTION

an antibody comprising the H chain variable region DNA contained in *Escherichia coli* DH5 α /pHKM1750HV0 DH5 α /phKM1750HV0 (FERM BP-6719) and the L chain variable region DNA contained in *Escherichia coli* DH5 α /phKM1750LV4 (FERM BP-6718), and

an antibody comprising the H chain variable region DNA contained in *Escherichia coli* DH5 α /pHKM1750HV3 DH5 α /phKM1750HV3 (FERM BP-6720) and the L chain variable region DNA contained in *Escherichia coli* DH5 α /phKM1750LV4 (FERM BP-6718).

19. (Original) The method according to claim 14, wherein the antibody fragment is an antibody fragment selected from the group consisting of Fab, Fab', F(ab')₂, a single chain antibody, a disulfide-stabilized Fv and a peptide comprising a complementarity determining region.

20. (Currently Amended) The method according to claim 11, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent ~~by a chemical or genetic engineering means~~.

Claims 21-65. (Canceled)

66. (Previously Presented) The method according to claim 11, wherein the cells or tissues are derived from blood.